

# Optimal target range of the CLIO2

No registrations found.

<b>Ethical review</b>	Positive opinion
<b>Status</b>	Pending
<b>Health condition type</b>	-
<b>Study type</b>	Observational non invasive

## Summary

### ID

NL-OMON25169

### Source

NTR

### Brief title

OPTICLIO study

### Health condition

Preterm infants, hyperoxemia, hypoxia, desaturation, oxygen saturation targets, closed loop inspired oxygen, CLIO.

## Sponsors and support

**Primary sponsor:** Academic Medical Center, Amsterdam

**Source(s) of monetary or material Support:** None

## Intervention

## Outcome measures

### Primary outcome

The primary outcome variable is defined as the proportion of time for all three target ranges with SpO2 within the assigned saturation ranges currently used in the clinical setting, being 86%-94%, minus time with SpO2 above the assigned target range while FiO2 is set at 0.21.

### Secondary outcome

Several secondary endpoints will be collected and calculated:

1. the proportion of time in between the FiO<sub>2</sub> adjustment periods a) hypoxemia defined as SpO<sub>2</sub> < 80% and b) hyperoxemia defined as SpO<sub>2</sub> > 98% while FiO<sub>2</sub> > 0.21 between the different target ranges.
2. the distribution of SpO<sub>2</sub> between the three different periods of target ranges of automatic adjustment of FiO<sub>2</sub>. This will specifically include the comparisons of the 5th, 25th, 50th, 75th, and 95th percentiles.
3. the fraction of inspired oxygen between the three periods of targets ranges of automatic adjustment of FiO<sub>2</sub>. For this, the mean, standard deviation, median interquartile and hourly-median FiO<sub>2</sub> will be calculated over each recording period.
4. the proportion of time with FiO<sub>2</sub> at 0.21 between the three periods of target ranges of automatic adjustment of FiO<sub>2</sub>.
5. the variability of SpO<sub>2</sub> between the three periods of target ranges of automatic FiO<sub>2</sub> adjustment. This will specifically include the coefficient of variation (Standard deviation divided by the mean) of SpO<sub>2</sub> over each recording period.
6. the frequency and duration of episodes with SpO<sub>2</sub> below the target range between the three periods of different target ranges of automatic FiO<sub>2</sub> adjustment.
7. the proportion of time with SpO<sub>2</sub> below the target range between the three periods of of different target ranges of automatic FiO<sub>2</sub> adjustment. This will specifically include the proportion of time with SpO<sub>2</sub> below the target range, SpO<sub>2</sub> < 80%, SpO<sub>2</sub> < 70%, SpO<sub>2</sub> between 80-86%, and SpO<sub>2</sub> between 80 % and the lower limit of the assigned target range.
8. the frequency and duration of episodes with SpO<sub>2</sub> above the target range between the three periods of automatic FiO<sub>2</sub> adjustment.
9. the proportion of time with SpO<sub>2</sub> above the target range while FiO<sub>2</sub> > 0.21 between the three periods of different target ranges of automatic FiO<sub>2</sub> adjustment.
10. the oxygen saturation status following pulse oximeter signal drop-out between periods of automatic FiO<sub>2</sub> adjustment. The oxygen saturation status will be defined as SpO<sub>2</sub> within, above or below the assigned target range for at least 10 seconds within the first minute after drop-out ends (i.e. Initial status) and at least 60 seconds over the first two minutes after the drop-out ends (i.e. Persistent status).
11. the rate of overshoot status following episodes when SpO<sub>2</sub> decreased below the target range between periods of automatic FiO<sub>2</sub> adjustment. This will be defined as SpO<sub>2</sub> above the target range for at least 10 seconds over the first minute following recovery from an episode of SpO<sub>2</sub> below the target range (Initial overshoot status) and as SpO<sub>2</sub> above the target range for at least 60 seconds over the first two minutes following recovery from an episode of SpO<sub>2</sub> below the target range (Persistent overshoot status).

## Study description

### Background summary

Both hypoxia and hyperoxia can lead to organ damage in preterm infants. For this reason the transcutaneously measured oxygen saturation (SpO<sub>2</sub>) is kept within a range between 86% and

95%. Hypoxia is mainly caused by immature or impaired control of breathing (apnea) and/or a compromised lung function. Hypoxia is often treated with supplemental oxygen, which is manually adjusted to keep the SpO<sub>2</sub> within the target range. However, due to clinical instability and the limited time nurses have to adjust the amount of oxygen, preterm infants only spent approximately 50% of the time within the SpO<sub>2</sub> target range. Recent studies have shown that the automatic fractional inspired oxygen (FiO<sub>2</sub>) function of the AVEA ventilator is more capable of maintaining preterm infants within preset saturation ranges than manual adjustment. However, it is unknown to what extent narrowing the SpO<sub>2</sub> target range during automated control will result in a tighter control of the SpO<sub>2</sub>.

This randomized controlled cross-over trial will assess the optimal target range of the automatic FiO<sub>2</sub> function by maintaining the same mean, and narrowing the upper and lower limits of the target range.

## **Study objective**

Both hypoxia and hyperoxia can lead to organ damage in preterm infants. For this reason the transcutaneously measured oxygen saturation (SpO<sub>2</sub>) is kept within a range between 86% and 95%. Hypoxia is mainly caused by immature or impaired control of breathing (apnea) and/or a compromised lung function. Hypoxia is often treated with supplemental oxygen, which is manually adjusted to keep the SpO<sub>2</sub> within the target range. However, due to clinical instability and the limited time nurses have to adjust the amount of oxygen, preterm infants only spent approximately 50% of the time within the SpO<sub>2</sub> target range. Recent studies have shown that the automatic fractional inspired oxygen (FiO<sub>2</sub>) function of the AVEA ventilator is more capable of maintaining preterm infants within preset saturation ranges than manual adjustment. However, it is unknown to what extent narrowing the SpO<sub>2</sub> target range during automated control will result in a tighter control of the SpO<sub>2</sub>. The hypothesis of this trial is that narrowing the target range of the automatic FiO<sub>2</sub> function by maintaining the same mean, and narrowing the upper and lower limits of the target range, will result in an increased proportion of time within the target ranges.

## **Study design**

Not applicable

## **Intervention**

Infants enrolled in the study will randomly undergo three study periods of 24 hours each by the automatic function in the AVEA ventilator, one with target ranges of SpO<sub>2</sub> set to 86% (lower limit (LL)) to 94% (upper limit (UL)), one with target ranges of SpO<sub>2</sub> set to 88% LL and 92% UL SpO<sub>2</sub>, and one with target ranges of SpO<sub>2</sub> set to 89% (LL) and 91% (UL). Random assignment to each target range of SpO<sub>2</sub> will be done immediately prior to the start of the study procedures in each enrolled infant. In order to minimize the effect of the previous assigned target range, the infants will receive 24 hours of standard care switching off the automatic function after the first and second target range during 24 hours as a wash-out period. Infants will remain in the study for a period of 120 hours. At the end of which, they

will exit the study.

## Contacts

### **Public**

Emma Childrens Hospital/AMC  
Department of Neonatology

W. Onland  
Meibergdreef 9

Amsterdam 1105 AZ  
The Netherlands  
+31 (0)20 5669111

### **Scientific**

Emma Childrens Hospital/AMC  
Department of Neonatology

W. Onland  
Meibergdreef 9

Amsterdam 1105 AZ  
The Netherlands  
+31 (0)20 5669111

## Eligibility criteria

### **Inclusion criteria**

Preterm infants, born with a gestational age between 23 and 32 weeks, and a weight at study entry between 0.4 to 4 kilograms, needing non-invasive respiratory support by the AVEA ventilator with a supplemental oxygen  $> 0.21$  for more than 18 hours per day.

### **Exclusion criteria**

The eligible preterm infants will not have one of the following exclusion criteria: major congenital anomalies, arterial hypotension requiring vasopressor therapy within 48 hours prior to enrollment, culture proven sepsis within 72 hours prior to enrollment, or if the

attending physician deems participation in the study is not in the best interest of the infant

## Study design

### Design

Study type:	Observational non invasive
Intervention model:	Crossover
Allocation:	Randomized controlled trial
Masking:	Open (masking not used)
Control:	N/A , unknown

### Recruitment

NL	
Recruitment status:	Pending
Start date (anticipated):	01-02-2014
Enrollment:	41
Type:	Anticipated

## Ethics review

Positive opinion	
Date:	08-01-2014
Application type:	First submission

## Study registrations

### Followed up by the following (possibly more current) registration

No registrations found.

## Other (possibly less up-to-date) registrations in this register

No registrations found.

## In other registers

Register	ID
NTR-new	NL4224
NTR-old	NTR4368
Other	2013_217#B2013801a : METC ID

## Study results

### Summary results

None